Arvinas Inc

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial Officer (CCO).

Arvinas Appoints John Northcott as Chief Commercial Officer

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar?

NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13 at 4:20 p.m. ET / 1:20 p.m. PT in Rancho Palos Verdes, Calif.

Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, has fallen 24% in a month, while it's down a significant 49% YTD.

Down 24% In A Month, Will Arvinas Stock Rebound?

Arvinas announced decent data from ARV-110 in February. The market may have expected more.

Arvinas: Still Holding, Just Not Buying More

SOMERVILLE, Mass., May 9, 2022 /PRNewswire/ -- GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical companies, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases.

GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration

NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences:

Arvinas to Present at Upcoming Investor Conferences

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates

NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA 50 rate and durable RECIST responses –

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer

Bath and Body Works

VTEX

The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination of the omicron fears, and the anticipation of the Fed raising rates to curb the surge of inflation. This has led to a growing concern about the possibility of a bear market this year.

3 Stocks To Double Down On In 2022

BOSTON--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Marcia Moore as Chief Operating Officer. Ms. Moore joins Cardurion from Arvinas, Inc., bringing more than three decades of pharmaceutical and biotechnology industry experience in clinica

Cardurion Pharmaceuticals Enhances Leadership Team with Appointment of Marcia Moore as Chief Operating Officer

Kymera Therapeutics

Pfizer

Is it time to buy a basket of biotech stocks?

3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch

Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110). The data were shared at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.

Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients

– Bavdegalutamide demonstrated a 46% PSA 50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations –

Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting

ARVN is doing superb, interesting science. If successful, this company could become a game-changer. They have some upcoming catalysts.

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Apellis Pharma

Axsome Therapeutics

Coursera

Fate Therapeutics

Global Blood Therapeutics

Karuna Therapeutics Inc

Sunnova Energy International Inc

PDC Energy Inc

Rocket Pharma

Tenable Holdings Inc

Varonis Systems

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

12 Super Small-Cap Stocks to Buy for 2022 and Beyond

Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).  ARV-471 demonstrated antitumor activity in CDK4/6 inhibitor-pretreated patients with a clinical benefit rate (CBR) of 40% in 47 evaluable patients.

Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients

– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium –

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471, a novel oral estrogen receptor (ER)-targeting PROteolysis TArgeting Chimera (PROTAC®) protein degrader, will be presented in a spotlight poster-discussion session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-10, 2021. ARV-471 is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium

Arvinas was founded by Dr. Craig Crews, the pioneer in the field of targeted protein degradation.

Arvinas: 2022 Is Full Of Catalysts For This Protein Degrader Pioneer

NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16 at 10:40 a.m. ET.

Arvinas to Present at Stifel 2021 Virtual Healthcare Conference

NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

News for Arvinas Inc Stock (ARVN)